A new analysis of data has found that growing numbers of people are using the experimental peptide BPC-157 to treat a wide range of conditions, even though there is still almost no evidence confirming its safety and effectiveness in humans. The substance has been championed by Robert F. Kennedy Jr., the U.S. health secretary, and is advertised online as helping to relieve pain, aid recovery and boost performance. The U.S. Food and Drug Administration has not approved BPC-157 as a drug, yet it remains highly popular in the gray market, which exploits legal loopholes, and users often pair it with the peptide TB-500 in a popular combination known as the Wolverine Stack. Last July, an FDA advisory committee voted in favor of allowing pharmacies to compound BPC-157 for individual patients with a prescription, driven by Kennedy, in a reversal of the agency's earlier stance of tightening controls on such compounding. Analysts estimate that if this group of peptides were properly approved under the law, the market could reach 2 billion to 3 billion U.S. dollars. Tracking real-world use of BPC-157 is difficult because the substance has no drug code in U.S. systems, so the data analytics firm nference instead examined more than 15 million medical records and found 1,039 patients whose doctors recorded that they had used the peptide, with the number of new users rising 33-fold between 2020 and 2026. Among 644 patients whose reasons were recorded, most began using it to relieve pain or treat gastrointestinal conditions, as well as sports injuries and chronic pain, and most obtained the drug from compounding pharmacies or gray-market peptide sellers. Vengkee Soonthornrachan, head of the nference research team, said the analysis makes the popularity of BPC-157 clearer, but the picture remains incomplete because actual use is likely far higher. The research report, which has not yet been peer-reviewed, also noted that only one in three patients had their treatment outcomes recorded by a doctor. Among those who stopped using the drug, the main reason was that a doctor told them to stop, while some had to stop because of side effects such as neurological and mood disorders, skin symptoms and gastrointestinal problems.
nference conducted the medical-records analysis showing BPC-157 use rose 33-fold, but the article reports no financial or business impact on the firm.
